S&P 500 component Moderna, Inc. (MRNA) climbed 4.8%, extending its rebound momentum from Monday's session. The vaccine sector broadly declined last Friday after Trump administration health officials announced plans to present claims this week to a key vaccine advisory committee under the U.S. Centers for Disease Control and Prevention (CDC) regarding alleged connections between COVID-19 vaccines and 25 pediatric deaths.